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Hematopoiesis is one of the best studied adult stem-cell systems, with a differentiation hierarchy progressing from immature
hematopoietic stem cells to over 10 distinct mature cell types. Recent technological breakthroughs now make it possible to deﬁne
transcriptional proﬁles in thousands of individual cells. Facilitated by the wealth of prior data on cell puriﬁcation and analysis strategies,
hematopoiesis has been one of the earliest experimental systems to which many of these new single-cell sequencing technologies
have been applied. In this review, the authors focus on recent studies, which have shed light on heterogeneity within individual
populations as well as the relationships between populations, and also attempt to characterize the differences between normal and
disease/perturbed states.Background constant supply of blood cells, and can respond to systemHematopoiesis is one of the best studied adult stem cell (SC)
systems, presumably at least in part due to the ease of sample
accessibility and the detailed phenotypic and functional charac-
terization that exists for the various immature and mature blood
cell types. Hematopoiesis is often thought of as a step-wise
process, which begins at the top of a tree-like structure (the
hematopoietic tree) with hematopoietic stem cells (HSCs) at the
apex, followed by step-wise branching points via a series of
deﬁned progenitor stages to the various differentiated andmature
cell types.1 Each cell type at the individual stages can be
characterized by its surface phenotype using ﬂuorescence
activated cell sorting (FACS) and functionally according to its
output using in vivo and/or in vitro assays.
The prime function of adult hematopoietic stem/progenitor
cells (HSPCs) is to maintain homeostasis within the organism and
produce a balanced output of all of the required mature blood
cells for the lifetime of the organism. This stability is determined
by the ability of HSCs to self-renew, differentiate, or remain
quiescent, thereby ensuring that the organism will have aKW and BG wrote the article.
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1perturbations such as injury and infection.2 In the case of
leukemia or other serious blood disorders, normal homeostasis
becomes dysregulated and the status-quo is lost.3,4 Importantly,
cell fate choices such as self-renewal and differentiation are made
at the level of individual single cells, and yet must be coordinated
(most likely by both intrinsic and extrinsic factors) to maintain
the overall balance of the system.5,6 Of note, the exact structure of
the hematopoietic tree is still hotly debated, as is the extent of
heterogeneity within cell populations, the exact process of lineage
decision making and how these decisions are perturbed in
disease.7 Single-cell molecular proﬁling has emerged as a new and
powerful experimental tool to advance our understanding of all
of these points.
Hematopoietic research has long focused on individual single
cells. The long-established colony assay, for example, reads out
the ability of an individual cell to give rise to a colony of blood
cells, and then based on the mature cell types generated, assigns a
given progenitor function in this essentially retrospective assay.
Similarly, the ultimate gold standard to determine whether a
given cell is a HSC is to perform single-cell transplantations and
evaluate its ability to reconstitute the blood system of an
irradiated recipient.8–12 Importantly, hematopoiesis research has
a long-track record of pioneering new techniques and single-cell
biology is not novel to the twenty-ﬁrst century. It has long been
recognized that bulk RNA-Seq can provide global gene
expression where a general overview of a homogeneous
population is required, but it will not provide speciﬁc information
regarding the gene expression changes, which occur on a cell-to-
cell basis. This information can be important when trying to look
at a heterogeneous cell population and the stochastic processes
taking place or the response of a particular cell type to a stimulus
(Fig. 1). Single-cell transcriptome analysis of the hematopoietic
system was already taking place in 1990, beginning with work in
the laboratory of Norman Iscove, which demonstrated that
low abundance transcripts could be detected from single cells in a
cell-speciﬁc manner.13 By 1996, Hu et al had been able to adapt
real-time polymerized chain reaction (RT-PCR) methods to the
Figure 1. Cellular heterogeneity can be resolved by single-cell molecular proﬁling. Classical bulk gene expression analysis generates population average
measurements, which obscure any information about heterogeneity between individual cells. Importantly, cellular heterogeneity is pervasive across many biological
settings, including both normal and malignant hematopoiesis. Modern single-cell molecular proﬁling technologies can resolve cell-to-cell heterogeneity, and thus
provide new insights into normal differentiation processes and their underlying regulatory networks, cellular responses to external signals and the heterogeneous
cell states present during leukemia development.
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ous nature of multipotent progenitor cells, whereby single multi-
potent cells expressed multiple “lineage-speciﬁc” gene programs
proceeding commitment to a speciﬁc cell lineage.14 This was a
landmark paper, which unequivocally showed that the different
lineageprograms couldbedetected inone individual cell rather than
speciﬁc subpopulations of the progenitor compartment.
While the techniques developed in the 1990s enabled
measurements of gene expression at the single-cell level, the
techniques were laborious, low throughput and not quantitative.
The next leap in single-cell technologies came with the use of
microﬂuidics to highly parallelize quantitative RT-PCR (qRT-
PCR) from single cells,15 and mixing the ampliﬁed cDNA with
PCR reagents in nanoliter volumes to improve reaction efﬁciency
and save on reagent costs. This technology was subsequently
commercialized by the establishment of Fluidigm® and the release
of the Fluidigm BiomarkTM system, which greatly facilitated
expansion of single-cell molecular proﬁling to a wider range of
laboratories. While this technology works very efﬁciently, the
microﬂuidics approach had several caveats, with 2 of the most
inﬂuential being the cost and the restriction in terms of the
number of handpicked genes which could be analyzed.
To address these shortcomings and analyze more cells and
more genes, researchers developed protocols that enabled single-
cell RNA sequencing (scRNA-Seq). While the initial protocol was
low throughput and expensive,16 the Smart-Seq2 protocol
published by Picelli et al17 allows more efﬁcient mRNA2sequencing from a single cell, and can be parallelized either
following a plate-based method as in the original protocol or
implemented on microﬂuidic chips developed by Fluidigm (up to
800 cells in 1 experiment). The Smart-Seq2 protocol is of
relatively lower cost than any preceding technology and the
processing time is comparatively quick. To isolate single cells,
complex populations are typically puriﬁed further by FACS. If
plates are to be used, this also enables the collection of FACS
index information, which records precise ﬂuorescence values for
each individual cell, and thus provides potentially powerful
metadata for subsequent analysis.18
For routine analysis of cell numbers that exceed the low
hundreds, Smart-Seq2-based protocols, however, remained cost
prohibitive. In the quest of alternatives, the largest reduction in
cost of scRNA-Seq has come about from protocols such as Drop-
Seq and inDrops,19,20 which allow a much larger number of cells
to be processed bringing down the cost per cell. Brieﬂy, the Drop-
Seq protocol is based around encapsulating single cells and the
reagents required for cDNA synthesis in a nanoliter droplet using
a microﬂuidic device. The cells are then lyzed within the droplet
and cDNA synthesis performed. During cDNA synthesis unique
cell barcodes (and unique molecular identiﬁers [UMIs]) are
incorporated into the molecules. This means that each cell has a
unique barcode and each transcript from within that cell will
contain a UMI. The use of UMIs allows counting of individual
transcripts, thereby preventing the same transcript been counted
repeatedly. This was a problemwith other scRNA-Seq techniques
Figure 2. Summary of single-cell RNA sequencing methods
discussed in this review. Representation of how evolving technologies
are permitting the scaling of cell and transcript/gene number. Source
references.17,19,20,23,24,31,61,62 An average has been taken for genes/
transcripts when a range was given in the original text.
(2018) 2:2 www.hemaspherejournal.comas PCR duplication (the same transcript counted multiple times)
was difﬁcult to control. After cDNA synthesis the cells are pooled,
ampliﬁed, and a sequencing library produced. A commercial
provider (10 Genomics®) has now entered the marketplace
ensuring more widespread availability and adaption of the
technology. The commercial ChromiumTM platform from 10
Genomics®, for example, permits the capture of up to 10,000
cells in <6 minutes, and costs for generating sequencing libraries
are very cheap on a per-cell basis, because the use of barcodes
permits pooling of cDNAs prior to library generation. There are
of course caveats with the Drop-Seq/inDrop protocol, as the
sequencing data are much shallower when compared with the
Smart-Seq2 protocol and cell surface marker information is lost.
For a researcher needing to make a choice about which
technology to use, this commonly becomes a balance between cell
number, read depth, and cost.21 Of note, new protocols reported
recently allow the simultaneous capture of epitope and tran-
scriptome,22 which now opens up the opportunity of recording
speciﬁc cell surface markers as part of droplet-based scRNA-Seq
protocols. Other protocols recently reported include Seq-Well,23
which takes advantage of the Drop-Seq processing method but
has no requirement for the capture of cells in droplets. Instead,
single cells are captured into wells of a chip using gravity, relying
on the fact that the well size will only permit one bead and an
individual cell. Importantly, this allows visual inspection of cells,
and in due course may be adapted to high content multichannel
cell imaging. The commercial Wafergen ICELL8 platform
follows a similar concept, and allows for the isolation and
processing of 1800 single cells which are all veriﬁed visually, so
that only wells in which cells meet the predeﬁned criteria are
processed further. When choosing which technique to use for an
experiment it is important to weigh the beneﬁts against the
caveats of each technique. While Smart-Seq2 gives a greater
coverage of genes it is lower throughput and more expensive per
cell when compared with Drop-Seq (or equivalent). Drop-Seq
and 10ChromiumTM on the other hand can process manymore
cells but the gene coverage is much shallower meaning that it may
be difﬁcult to characterize cells, which have a low transcriptional
rate or are quiescent (Fig. 2).
One of the main advantages of the ultra-high throughput
protocols (Drop-Seq, 10ChromiumTM, Seq-Well, and ICELL8)
is the inclusion of UMIs. Using combinations of cell barcodes,3UMIs, and sequencing library indexes, thousands of individual
cells can be pooled together reducing the number of samples to be
processed but also ensuring that transcripts are only counted once
(to avoid artifacts from PCR duplicates). Much of the Drop-Seq/
inDrop data when compared with Smart-Seq2 data would appear
as binary data, with genes either detected once or not at all. One
of the most likely underlying reasons is that UMI-based methods
only count the very 30 end of each transcript, whereas the Smart-
Seq2 protocol can generate sequence reads along the entire
reverse transcribed cDNA. A recent development in the single-cell
ﬁeld is that of split barcodes, which enables the processing of
large numbers of cells by taking advantage of combinatorial
indexingmethods.While single-cell combinatorial indexing RNA
sequencing (sci-seq)24 incorporates different indexes at the
mRNA and PCR stages, Split Pool Ligation-based Transcriptome
sequencing (SPLiT-seq)25 uses in situ ligation to link a well-
speciﬁc DNA barcode onto the 50 end of the cDNA molecule as
well as incorporating UMIs to allow molecule counting. This
process of repeat barcoding ensures that the probability of 2 cells
containing the same cell barcode is very low, and that detection of
doublets will be easier upon demultiplexing of the samples. These
ground-breaking techniques have the potential to revolutionize
scRNA-Seq as they will allow the analysis of thousands of cells in
a single experiment and drastically reduce the price of processing.
The most important consideration when making a choice about
which technology to use remains that this needs to be driven by
the scientiﬁc question. One further issue is that with ever larger
cell numbers, the challenge of interpreting the data grows
substantially.26Advancing our understanding of nonmalignant
hematopoiesis by single-cell sequencing
The hematopoietic research ﬁeld was an early adopter of scRNA-
Seq technology, which has now been used to investigate a number
of different hematopoietic cell types from both human and
mouse. While this review focuses on adult hematopoiesis, a
substantial amount of research is also focusing on developmental
hematopoiesis,27 with single-cell approaches relevant not just
because of the limiting cell numbers, but also because it is
increasingly recognized that there is substantial cellular hetero-
geneity right from the earliest stages of blood development.28 Of
note, some early applications of single-cell expression proﬁling to
embryonic hematopoiesis are already making a large impact,29
highlighting the ﬁrst whole transcriptome analysis of early
mesoderm formation,30 implicating previously unrecognized
pathways in tissue development31 as well as shedding light on
the speciﬁc roles of individual transcription factors (TFs) during
development.30,32 For adult hematopoiesis, different approaches
have been taken when isolating cells, from a more general sorting
strategy which captures multiple cell types (eg, HSCs and
progenitors [LinSca1+c-Kit+], myeloid progenitors [Linc-
Kit+Sca1]) to more restrictive strategies which speciﬁcally
isolate individual cell populations (eg, granulocyte monocyte
progenitors [GMP], common myeloid progenitors [CMP], and
speciﬁc subtypes of dendritic cells). Some of the ﬁrst studies took
advantage of scRNA-Seq and indexomics (FACS index sorting),
for example, to reﬁne cell sorting strategies for HSCs, which
resulted in a purer population which had over 65% transplanta-
tion efﬁciency when assayed by single-cell transplantation/long-
term reconstitution experiments.33 A second study went further,
and molecularly proﬁled dormant HSCs.34 This study showed
that there was a gradual molecular progression toward activation
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transcriptional programs which were involved at each progres-
sive step. Other studies have analyzed the differences between
young and agedHSCs, showing that the one of the largest varying
factors is cell cycle,35,36 as well as increased myeloid gene
expression.36 A further study focused on aged progenitor cells
(LMPP/MPP4) and showed that in addition to cell cycle effects in
the progenitor cells, there was also a reduction in lymphoid
priming genes.36 A study investigating the effect of stress
(bleeding) on HSPCs showed that induced anemia causes cell
cycle changes in both HSCs and MPP1 cells,37 yet expression
changes were more nuanced with HSCs upregulating Sca1
expression and immune response genes whereas MPP1 cells
upregulated granulocytic, megakaryocytic, and erythroid genes.
Of note, this study suggests that there may be a link between cell
cycle stage and the ability to respond to external stimuli, which
would impact the self-renewal/differentiation decision-making
processes of many progenitor cell types, and be particularly
relevant for quiescent HSCs.
An important focus to date within normal hematopoiesis
research has been to delineate the extent of heterogeneity within
classically deﬁned hematopoietic cell populations. An important
consideration here is the need to determine the difference between
the generic heterogeneity (driven by processes occurring across all
cell types such as cell cycle) and informative heterogeneity which
is driving differences in functional outcome between cell
populations. A second major focus has been to identify the
genes, which are responsible for driving lineage determination. A
prime example of this can be found in a landmark study by the
Amit lab, in which they set out to characterize the transcriptional
diversity of myeloid progenitors.38 Importantly, this study took
an unbiased approach to map the transcriptional landscape of
myeloid progenitors by performing scRNA-Seq (MARS-Seq39)
on over 2700 single cells (lin c-Kit+ Sca1). Bioinformatic data
analysis was able to separate the single cells into multiple
transcriptionally distinct clusters, which recapitulated known
gene expression patterns as well as implicate TFs never before
associated with speciﬁc lineages. The study also looked into the
transcriptional effects of perturbations of the hematopoietic
system, and demonstrated that although speciﬁc TFs where
associated with speciﬁc lineages, perturbation lead to different
effects on the different trajectories. Loss of Cebpa resulted in a
complete loss of speciﬁc clusters associated with myeloid
subgroups whereas loss of Cebpe lead to an increase of
neutrophil gene clusters. This study highlights the importance
of functional studies to test the hypothesis highlighted by
transcriptome analysis.
A comprehensive single-cell transcriptomic survey of the stem
and progenitor compartment was provided by a resource paper,
which proﬁled more than 1600 HSPCs using the Smart-Seq2
method,40 and provides a web interface that allows investigators
to query the expression of any gene of choice (http://blood.
stemcells.cam.ac.uk/single_cell_atlas.html). The aim of this study
was to interrogate the heterogeneity and proﬁle the higher tiers of
the hematopoietic tree at single-cell resolution to recapitulate the
earliest stages of the hematopoietic hierarchy at single-cell
resolution. The use of broad sorting gates coupled with
comprehensive FACS index information also facilitates the
investigation of dynamic processes which may take place during
speciﬁc lineage decisions, both at the cell surface marker
expression (using index data) and the transcriptomic level. As
illustrated by the authors,40 generating reference datasets for
normal HSPCs also permits the projection of additional scRNA-4Seq datasets, thus enabling comparison to and interpretation of
perturbed systems, which is then entirely driven by the underlying
molecular expression differences rather than having to rely on
external data sources such as gene ontology databases.
Comprehensive scRNA-Seq has also been used to dissect the
heterogeneity of mouse GMPs. To determine the most informa-
tive genes for this type of analysis, Olsson et al developed a new
iterative clustering and guide-gene selection (ICGS) algorithm,41
which uses pair-wise correlations of dynamically expressed genes
and iterative rounds of clustering to determine the most
inﬂuential genes within a given dataset. scRNA-Seq was
performed on deﬁned hematopoietic populations (HSPCs [LSKs,
LinSca1+c-Kit+], CMPs, GMPs, and LKCD34+ cells [linc-
Kit+CD34+]). ICGS analysis was then able to recapitulate the
hematopoietic hierarchy but more interestingly was also able to
subdivide the GMPs into 3 distinct regulatory states deﬁned by
TF–gene pairs. Reassuringly, this included known interactions
(Irf8–Klf4), but also identiﬁed previously unknown regulatory
interactions between speciﬁc TFs, such as Irf8 and Zeb2 as well as
reciprocal expression patterns between Irf8 and Gﬁ1. What sets
this study apart is that the authors then used this information to
capture the rare cells that undergo monocytes to neutrophil
speciﬁcation based on low-level expression of antagonizing TFs.
This is an illustration, therefore, how step-wise analysis allows us
to understand more of the complex processes involved in the
multistep process of lineage determination. Moreover, this paper
serves as an example highlighting the need for functional follow-
up to validate hypotheses generated by single-cell transcriptomic
studies.
Recent studies aimed to proﬁle the heterogeneity of the human
hematopoietic stem and progenitor compartment, and concluded
that it was not possible to resolve the HSPCs into HSCs and
oligopotent progenitors.42–44 One approach taken used Micro-
well-Seq43 to proﬁle more than 50,000 human hematopoietic
cells from GCSF mobilized peripheral blood donors, which
recapitulated the multiple different lineages of the hematopoietic
system using the Seurat analysis package.45 The second study
isolated HSPCs (LinCD34+CD38) and committed progenitors
(LinCD34+CD38+) from healthy bone marrow and performed
scRNA-Seq.42 In an attempt to deﬁne the transition during
lineage commitment from SCs to committed progenitors, Velten
et al42 developed a computational tool (STEMNET) to
reconstruct differentiation trajectories. The STEMNET algo-
rithm uses genes speciﬁc to the committed progenitors to try to
determine the lineage priming of a HSPC. This algorithm is
efﬁcient at separating the more committed and intermediate
progenitors, but failed to identify clear subgroups within the most
immature compartment of the HSPCs. Coupled with compre-
hensive single-cell culture assays, this lead the authors to conclude
that adult human HSPCs exist in a continuum of lowly primed
expression states, that rapidly progress to unilineage progenitors
with little discernible multipotent progenitor states. This idea
therefore challenged more conventional models where the
process of lineage speciﬁcation was thought to be mediated by
the step-wise progression of expressing sequential gene modules
from multi- to oligo- and ultimately unipotent progenitors.46 It
will be interesting to see if oligopotent progenitors can be
identiﬁed within the HSPC compartment using different analysis
techniques which do not rely on gene sets deﬁned by already
committed progenitors (Fig. 3).
In a more directed approach, Villani et al47 set out to
characterize subtypes of human dendritic cells (LinHLA-
DR+CD14) and monocytes (LinCD14lo/++). Unsupervised
Figure 3. The hematopoietic hierarchy in the era of single-cell gene expression analysis. The exact structure of the hematopoietic tree is still hotly
debated. (i) A representation of the classical hematopoietic tree, where cells advance in a step-wise progression of differentiation and maturation, from HSCs to
mature cell types. (ii) Representation of a more continuous model of differentiation based on recent studies suggesting that hematopoietic stem/progenitor cells
cannot easily be resolved into speciﬁc HSC and progenitor populations. HSC, hematopoietic stem cell.42,43
(2018) 2:2 www.hemaspherejournal.comanalysis of the dataset made it possible to identify combinations
of speciﬁc cell surface markers, which permitted the isolation of
purer dendritic subtypes. Interestingly, although overlapping
expression proﬁles of the 2 cell types could be seen, a common
precursor could not be identiﬁed. Monocytes were found to be
more heterogeneous than previously thought and in addition,
two previously unidentiﬁed subtypes were seen. Importantly, this
study not only identiﬁed new subtypes of dendritic cells based on
molecular proﬁles but then functionally supported this by
isolating a new subtype from multiple individuals followed by
visualization in situ within the tissue. The authors could also
isolate a more primitive progenitor cell and compare these cells to
previously published studies. While alone this study does not
provide an immune atlas it provides a useful resource and a more
comprehensive understanding of the role of dendritic cells in
tissues, inﬂammation, and disease.Advancing our understanding of malignant
hematopoiesis by single-cell sequencing
In the study of malignant hematopoiesis, much focus has
been placed on determining the clonogenicity, and this work
has investigated the heterogeneity at the level of the tran-
scriptome, epigenome, and resistance of clones to therapy.48–50
Many efforts have also been placed on determining not
only the driving mutations, which cause leukemia but also the
order of mutations and the arrangement of the perturbed
hematopoietic tree in disease. The focus of this section of the
reviewwill be the transcriptomes of malignant hematopoiesis and
the novel insights learned from using single-cell proﬁling
approaches.
An important aspect when studying blood cancers is that both
normal and malignant blood cells will be present within a given
patient sample. Each individual patient will have a different
disease burdenwhich to date has been a technical caveat of single-
cell technologies, because genotyping individual cells with low
false-negative rates represent a formidable challenge. It is self-
evident that knowledge of the mutational status of any given
single cell represents crucial information when analyzing its
transcriptome. Detection of mutation within the mRNA by
scRNA-Seq is heavily dependent on the location of the mutation,
because many of the current scRNA-Seq protocols are 30 biased.5Consequently, mutations which are a considerable distance from
the polyA site or are in a region which is difﬁcult to amplify (eg,
GC rich) cannot be reliably detected. Recently, Giustacchini
et al51 published a modiﬁcation to the Smart-Seq2 protocol,
which includes speciﬁc primers for the site of the mutation
(breakpoint region) within the BCR-ABL oncogenic fusion gene.
This allowed the detection of the mutant mRNA with a high
degree of accuracy, and thus enabled the separation of human
HSPCs from chronic myeloid leukemia (CML) patients into
BCR-ABL+ and BCR-ABL. Using a combination of single-cell
transcriptome proﬁling, mutation characterization, and cell
surface phenotype, the investigators were then able to determine
the heterogeneity at play within the cancer SCs. The authors
identiﬁed multiple gene sets, which were speciﬁcally enriched in
the BCR-ABL+ SC but could also detect genes, which were able to
differentiate BCR-ABL HSC in CML patients from normal
HSCs in control samples. By being able to sample at diagnosis
and then after treatment, the study could also retrospectively
predict how patients would respond to treatment from their gene
expression proﬁle, and see at diagnosis an enrichment of genes
associated with increased proliferation (MYC, E2F, and G2M-
checkpoint genes) for good responders and a more quiescent gene
proﬁle from poor responding patients. This type of analysis
highlights the importance of determining the mutational status of
individual cells from patients as well as sampling at diagnosis and
after treatment to have a greater predictive power for future
treatment regimes and pave the way for a more personalized form
of treatment.
To investigate the cooperative nature of Flt3 and Dnmt3a
mutations in leukemogenesis, Meyer et al52 crossed the mouse
lines to a myeloproliferative neoplasm model (Flt3ITD/ITD;
Dnmt3aﬂ/ﬂ) and acute myeloid leukemia (AML) model
(Flt3ITD/ITD; Dnmt3aﬂ/ﬂ MxCre). To characterize the AML
model, scRNA-Seq was performed and ICGS was run to identify
potential biomarkers, which could be used to access the
clonogenic properties of the AML. Expression of IL18ra and
c-Myc was shown to be signiﬁcantly enriched in cells with high
clonogenic potential, highlighting the possibility of IL18ra being
a surface marker for rare leukemic SCs. The study also
highlighted that differentially methylated regions associated with
HSPC genes could be reverted upon Dnmt3a rescue, highlighting
a potential therapeutic avenue.
3. Tenen DG. Disruption of differentiation in human cancer: AML shows
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Hematopoiesis has been at the forefront of single-cell technologies,
and theﬁeld is increasingly takingadvantageof these technologies to
address long-standing questions of broad relevance. With experi-
mental protocols maturing and datasets getting ever larger, a major
challenge going forward will be the interpretation of these datasets.
This includes the immediate issues of the need for large data storage
and computer processing power, but also extends to questions of
standardization and quality control, which will be essential to
performmeaningful cross interrogation between datasets generated
in different laboratories. Based on the early successes already
reported, it is likely that delving into the datasets will shed light and
new perspectives onto which factors, signaling molecules and
cascades contribute to the functional heterogeneity of convention-
ally deﬁned hematopoietic cell populations, what processes drive
lineage commitment, and how lineage plasticity can be predicted or
altered. In addition to proﬁling hematopoietic cells, it will also be
important to investigate the cells of the hematopoietic niche, not
only to characterize potential heterogeneity among different cells
that make up HSPC niches, but also to reveal potential cross-talk
between HSPCs and their respective niche cells.53 Incorporation of
additional layers of data may also be of use, for example, single-cell
chromatin accessibility or methylome data.54 Importantly, work on
normal hematopoiesiswill provide the foundation for applicationof
single-cell technology to disease states and pertubations, with the
real hope of identifying new therapeutic targets that would not be
revealed by conventional approaches.
While thiswould have been thought of as fanciful only a fewyears
ago, the production of large datasets is no longer the limiting factor,
while the downstream bioinformatic analysis, intellectual time and
thought invested into both the initial design and subsequent
interpretation of such vast datasets is now the bottleneck of these
types of experiments. The bioinformatic analysis of scRNA-Seqdata
is comprehensively covered in several reviews, which cover many
aspects from the gene-level analysis to cell-level analysis.26,55Mixing
the correct blend of investigators will be important as functional
studies are needed to complement the transcriptomics to be able to
functionally validate any signiﬁcant ﬁndings. Creating knockouts or
knock-inswas sucha laborious task several years agobutwith recent
developments in CRISPR-Cas9 technologies reasonably high-
throughput testing ofmultiple novel genes should be attainable.56,57
There have also been recent advances made combining CRISPR
technologies with scRNA-Seq, such as Perturb-Seq58,59 and CROP-
Seq.60 Approaches such as these once applied to the wider
hematopoietic system should begin to shed light on regulatory
modules which are playing important roles in hematopoietic
development. Finally, building and deepening links with clinicians
will also be crucial, because the potential of single-cell proﬁling for
improved diagnosis and/or patient stratiﬁcation can only be realized
if sample collection protocols are adapted so that they are geared to
maximize the quality of RNA for subsequent single-cell processing.
The futurewill lie in the interplay ofmultiple disciplines allowing the
further and more in-depth study of single cells. These collaborative
effortswill allowus to delve deeper into the regulatory networks and
transcriptional programs at play within both normal andmalignant
hematopoiesis.References
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